Skip to main content
SpringerLink
Log in

Managing Breast Cancer in Young Women

  • Chapter
Breast Cancer, Fertility Preservation and Reproduction

  • 706 Accesses

Abstract

Management of young patients with breast cancer still poses challenge to clinicians. Higher occurrence of aggressive intrinsic breast cancer subtypes and clinically advanced disease at diagnosis are observed in this patient population. Yet, they do not provide a full explanation for the poor clinical outcome observed in younger patients. Increasingly, the role tumor biology, irrespective of the underlying intrinsic breast cancer subtype, is being recognized as a predictor of worse outcome in young breast cancer patients.

Conflicting results of outcome studies have raised controversies regarding the role of chemotherapy in neoadjuvant and adjuvant settings in young patients, particularly in triple-negative and HER2-positive breast cancer. In ER-positive disease, debate also exist on the use extended hormonal therapy and aromatase inhibitors in the adjuvant setting in this patient population.

In this chapter, we will discuss different aspects related to the management of young breast cancer patients and provide treatment strategies based on current evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7.

    PubMed Central  PubMed  Google Scholar 

  2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.

    PubMed  Google Scholar 

  3. Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res BCR. 2010;12 Suppl 4:S8.

    Google Scholar 

  4. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg Lond Engl. 2007;5(4):225–33.

    Google Scholar 

  5. Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. J Natl Cancer Inst. 2013;105(13):978–88.

    CAS  PubMed  Google Scholar 

  6. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695.

    PubMed Central  PubMed  Google Scholar 

  7. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 1994;16:35–42.

    PubMed  Google Scholar 

  8. Han W, Kang SY. Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119(1):193–200.

    PubMed  Google Scholar 

  9. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr. 1994;16:69–77.

    PubMed  Google Scholar 

  10. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77(1):97–103.

    CAS  PubMed  Google Scholar 

  11. Rosenberg S. Choosing mastectomy over lumpectomy: factors associated with surgical decisions in young women with breast cancer. J Clin Oncol 31. 2013(Suppl; Abstr 6507).

    Google Scholar 

  12. Buckley J. Recurrence rates and long-term survival in women diagnosed with breast cancer at age 40 and younger. J Clin Oncol 29. 2011(Suppl 27; Abstr 70).

    Google Scholar 

  13. Cao JQ, Truong PT, Olivotto IA, Olson R, Coulombe G, Keyes M, et al. Should women younger than 40 years of age with invasive breast cancer have a mastectomy?: 15-year outcomes in a population-based cohort. Int J Radiat Oncol Biol Phys. 2014;90(3):509–17.

    PubMed  Google Scholar 

  14. Sheridan W, Scott T, Caroline S, Yvonne Z, Vanessa B, David V, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat. 2014;147(3):617–29.

    PubMed  Google Scholar 

  15. Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, et al. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1387–93.

    PubMed  Google Scholar 

  16. Migdady Y, Sakr BJ, Sikov WM, Olszewski AJ. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes. Breast Edinb Scotl. 2013;22(5):793–8.

    Google Scholar 

  17. Olszewski AJ, Migdady Y, Boolbol SK, Klein P, Boachie-Adjei K, Sakr BJ, et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Res Treat. 2013;138(1):215–23.

    CAS  PubMed  Google Scholar 

  18. Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2013;20(5):1436–43.

    PubMed  Google Scholar 

  19. Keegan THM, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res BCR. 2013;15(5):R95.

    Google Scholar 

  20. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92(10):2523–8.

    CAS  PubMed  Google Scholar 

  21. Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16:427.

    Google Scholar 

  22. Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in young women. J Am Coll Surg. 2000;190(5):523–9.

    CAS  PubMed  Google Scholar 

  23. Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 1996;78(8):1838–43.

    CAS  PubMed  Google Scholar 

  24. Gonzalez-Angulo AM, Broglio K, Kau S-W, Eralp Y, Erlichman J, Valero V, et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005;103(12):2466–72.

    PubMed  Google Scholar 

  25. Keegan THM, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res BCR. 2012;14(2):R55.

    CAS  Google Scholar 

  26. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061–6.

    CAS  PubMed  Google Scholar 

  27. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(20):3324–30.

    Google Scholar 

  28. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(5):1341–51.

    Google Scholar 

  29. Azim HA Jr, Azim H. Breast cancer arising at a young age: do we need to define a cut-off? Breast Edinb Scotl. 2013;22(6):1007–8.

    Google Scholar 

  30. Loving VA, DeMartini WB, Eby PR, Gutierrez RL, Peacock S, Lehman CD. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol. 2010;195(6):1472–7.

    PubMed  Google Scholar 

  31. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773–83.

    CAS  PubMed  Google Scholar 

  32. Pisano ED, Hendrick RE, Yaffe MJ, Baum JK, Acharyya S, Cormack JB, et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008;246(2):376–83.

    PubMed Central  PubMed  Google Scholar 

  33. Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol. 2004;183(4):1149–57.

    PubMed  Google Scholar 

  34. Peters NHGM, van Esser S, van den Bosch MA, Storm RK, Plaisier PW, van Dalen T, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET – randomised controlled trial. Eur J Cancer Oxf Engl 1990. 2011;47(6):879–86.

    CAS  Google Scholar 

  35. Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010;375(9714):563–71.

    PubMed  Google Scholar 

  36. Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg. 2013;257(2):249–55.

    PubMed  Google Scholar 

  37. McGhan LJ, Wasif N, Gray RJ, Giurescu ME, Pizzitola VJ, Lorans R, et al. Use of preoperative magnetic resonance imaging for invasive lobular cancer: good, better, but maybe not the best? Ann Surg Oncol. 2010;17 Suppl 3:255–62.

    PubMed  Google Scholar 

  38. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378(9805):1804–11.

    PubMed  Google Scholar 

  39. Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, et al. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg. 2006;192(1):58–62.

    CAS  PubMed  Google Scholar 

  40. National Comprehensive Cancer Network. Breast Cancer (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 10 Nov 2014.

  41. Wevers MR, Aaronson NK, Verhoef S, Bleiker EMA, Hahn DEE, Kuenen MA, et al. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial. Br J Cancer. 2014;110(4):1081–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  42. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(8):1250–6.

    CAS  Google Scholar 

  43. McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer. 2012;11(4):607–13.

    CAS  PubMed  Google Scholar 

  44. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MRE, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res. 2010;70(12):4795–800.

    PubMed Central  CAS  PubMed  Google Scholar 

  45. Botteri E, Bagnardi V, Rotmensz N, Gentilini O, Disalvatore D, Bazolli B, et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21(4):723–8.

    CAS  Google Scholar 

  46. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(6):1688–97.

    CAS  Google Scholar 

  47. De Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer Oxf Engl 1990. 2006;42(3):351–6.

    Google Scholar 

  48. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001;91(8 Suppl):1679–87.

    CAS  PubMed  Google Scholar 

  49. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.

    Google Scholar 

  50. Van Laar C, van der Sangen MJC, Poortmans PMP, Nieuwenhuijzen GA, Roukema JA, Roumen RMH, et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer Oxf Engl 1990. 2013;49(15):3093–101.

    Google Scholar 

  51. Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. J Am Coll Surg. 2014;219(1):19–28.

    PubMed  Google Scholar 

  52. McGuire KP, Santillan AA, Kaur P, Meade T, Parbhoo J, Mathias M, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16(10):2682–90.

    PubMed  Google Scholar 

  53. Bantema-Joppe EJ, de Munck L, Visser O, Willemse PHB, Langendijk JA, Siesling S, et al. Early-stage young breast cancer patients: impact of local treatment on survival. Int J Radiat Oncol Biol Phys. 2011;81(4):e553–9.

    PubMed  Google Scholar 

  54. Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014;21(10):3231–9.

    PubMed  Google Scholar 

  55. Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst. 2014;106(8):dju160.

    PubMed  Google Scholar 

  56. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(14):1507–15.

    Google Scholar 

  57. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(30):7703–20.

    Google Scholar 

  58. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.

    CAS  PubMed  Google Scholar 

  59. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32; discussion 432–3.

    PubMed  Google Scholar 

  60. Jones HA, Antonini N, Hart AAM, Peterse JL, Horiot J-C, Collin F, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(30):4939–47.

    Google Scholar 

  61. Bartelink H, Horiot J-C, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(22):3259–65.

    Google Scholar 

  62. Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.

    CAS  PubMed  Google Scholar 

  63. Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59–68.

    PubMed  Google Scholar 

  64. Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol J Eur Soc Ther Radiol Oncol. 2010;94(3):264–73.

    Google Scholar 

  65. Njeh CF, Saunders MW, Langton CM. Accelerated Partial Breast Irradiation (APBI): a review of available techniques. Radiat Oncol Lond Engl. 2010;5:90.

    Google Scholar 

  66. Veronesi U, Cascinelli N, Bufalino R, Morabito A, Greco M, Galluzzo D, et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg. 1983;198(6):681–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  67. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.

    Google Scholar 

  68. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    CAS  PubMed  Google Scholar 

  69. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

    PubMed Central  CAS  PubMed  Google Scholar 

  70. Van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.

    PubMed  Google Scholar 

  71. Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98(17):1183–92.

    CAS  PubMed  Google Scholar 

  72. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21(4):717–22.

    CAS  Google Scholar 

  73. Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(5):729–35.

    Google Scholar 

  74. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371(9606):29–40.

    Google Scholar 

  75. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(21):2692–8.

    CAS  Google Scholar 

  76. Tai P, Cserni G, Van De Steene J, Vlastos G, Voordeckers M, Royce M, et al. Modeling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer. 2005;5:130.

    PubMed Central  PubMed  Google Scholar 

  77. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(34):5700–6.

    Google Scholar 

  78. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(31):4952–60.

    Google Scholar 

  79. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

    Google Scholar 

  80. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(2):355–61.

    CAS  Google Scholar 

  81. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.

    PubMed Central  CAS  PubMed  Google Scholar 

  82. Gray R. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31. 2013(Suppl; Abstr 5).

    Google Scholar 

  83. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.

    PubMed Central  CAS  PubMed  Google Scholar 

  84. Huiart L, Bouhnik A-D, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer Oxf Engl 1990. 2012;48(13):1939–46.

    Google Scholar 

  85. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14(11):1067–76.

    PubMed Central  PubMed  Google Scholar 

  86. Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013;109(12):2959–64.

    PubMed Central  CAS  PubMed  Google Scholar 

  87. Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(5):1298–305.

    CAS  Google Scholar 

  88. Swain SM, Jeong J-H, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053–65.

    PubMed Central  CAS  PubMed  Google Scholar 

  89. Griggs JJ, Somerfield MR, Anderson H, Henry NL, Hudis CA, Khatcheressian JL, et al. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(29):3939–42.

    Google Scholar 

  90. Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(25):5973–82.

    CAS  Google Scholar 

  91. International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003;95(24):1833–46.

    Google Scholar 

  92. Arriagada R, Lê MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2005;16(3):389–96.

    CAS  Google Scholar 

  93. LHRH-Agonists in Early Breast Cancer Overview Group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711–23.

    Google Scholar 

  94. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.

    CAS  PubMed  Google Scholar 

  95. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.

    PubMed Central  PubMed  Google Scholar 

  96. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–41.

    CAS  PubMed  Google Scholar 

  97. Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014;32(35):3948–58.

    Google Scholar 

  98. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;375(5):436–46.

    Google Scholar 

  99. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(19):2653–9.

    CAS  Google Scholar 

  100. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010;124(1):133–40.

    CAS  PubMed  Google Scholar 

  101. Loibl S. Neoadjuvant chemotherapy in the very young, 35 years of age or younger. SABCS. 2012; Abstract S3-1.

    Google Scholar 

  102. Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–52.

    CAS  PubMed  Google Scholar 

  103. Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  104. Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida M, Veronesi P, et al. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat. 2011;126(2):431–41.

    CAS  PubMed  Google Scholar 

  105. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast Edinb Scotl. 2014;23(5):489–502.

    CAS  Google Scholar 

  106. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer Oxf Engl 1990. 2012;48(18):3355–77.

    Google Scholar 

  107. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(2):343–53.

    CAS  Google Scholar 

  108. Roché H. Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: a phase II trial. J Clin Oncol. 2009(2715s Suppl; Abstr 1079).

    Google Scholar 

  109. Nishimura R. Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: a phase II trial. J Clin Oncol. 2012(30 Suppl; Abstr 588).

    Google Scholar 

  110. Forward DP, Cheung KL, Jackson L, Robertson JFR. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004;90(3):590–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  111. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan S-C, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(25):3917–21.

    CAS  Google Scholar 

  112. Park IH, Ro J, Lee KS, Kim E-A, Kwon Y, Nam B-H, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(16):2705–11.

    CAS  Google Scholar 

  113. Yao S, Xu B, Li Q, Zhang P, Yuan P, Wang J, et al. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer. Endocr J. 2011;58(6):509–16.

    CAS  PubMed  Google Scholar 

  114. Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JFR, Winterbottom L. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer Oxf Engl 1990. 2010;46(16):2936–42.

    CAS  Google Scholar 

  115. Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer Oxf Engl 1990. 2012;48(13):1932–8.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, BrEAST Data Centre, Boulevard de Waterloo, 121, 1000, Brussels, Belgium

    Joyce G. Habib & Hatem A. Azim Jr.

Authors
  1. Joyce G. Habib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hatem A. Azim Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hatem A. Azim Jr. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Torino School of Medicine, Mauriziano Umberto I Hospital, Torino, Italy

    Nicoletta Biglia

  2. Fertility and Procreation Unit, Istituto Europeo di Oncologia, Milano, Italy

    Fedro Alessandro Peccatori

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Habib, J.G., Azim, H.A. (2015). Managing Breast Cancer in Young Women. In: Biglia, N., Peccatori, F. (eds) Breast Cancer, Fertility Preservation and Reproduction. Springer, Cham. https://doi.org/10.1007/978-3-319-17278-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17278-1_2

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17277-4

  • Online ISBN: 978-3-319-17278-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation